-
公开(公告)号：US10526390B2
公开(公告)日：2020-01-07
申请号：US15586010
申请日：2017-05-03
申请人： Ferring B.V.
IPC分类号： C07K14/575 , C07K14/59 , C12P21/00 , A61K38/16
摘要： The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include α2,3, α2,6, and, optionally, α2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
-
公开(公告)号：US09676835B2
公开(公告)日：2017-06-13
申请号：US14283904
申请日：2014-05-21
申请人： Ferring B.V.
IPC分类号： C07K14/575 , C12P21/00 , C07K14/59 , A61K38/16
CPC分类号： C07K14/575 , A61K38/16 , C07K14/59 , C12P21/005
摘要： The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include α2,3, α2,6, and, optionally, α2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
-
公开(公告)号：US10519218B2
公开(公告)日：2019-12-31
申请号：US15532097
申请日：2015-12-01
申请人： Ferring B.V.
发明人： Ian Cottingham , Daniel Plaksin , Jérémy Duboeuf
IPC分类号： C07K14/715 , C12N15/63 , A61K38/17 , A61K38/00
摘要： A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
-
公开(公告)号：US20180030107A1
公开(公告)日：2018-02-01
申请号：US15586010
申请日：2017-05-03
申请人： Ferring B.V.
IPC分类号： C07K14/575 , C07K14/59
摘要： The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include α2,3, α2,6, and, optionally, α2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
-
公开(公告)号：US10952959B2
公开(公告)日：2021-03-23
申请号：US16477127
申请日：2018-01-11
申请人： Ferring B.V.
发明人： Ganeshchandra Sonavane , Daniel Plaksin , Varinder Ahuja , Parag Lokhande , Devendra Kantilal Jain
IPC分类号： A61K9/00 , A61K38/095 , A61K9/19 , A61K9/20 , A61K31/404 , A61K31/47 , A61K31/4985 , A61K31/519
摘要： The subject invention is directed to a pharmaceutical composition comprising an open matrix network incorporating one or more pharmaceutically active ingredients, wherein the open matrix network comprises maltodextrin and hyaluronic acid or a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US20140249082A1
公开(公告)日：2014-09-04
申请号：US14283904
申请日：2014-05-21
申请人： Ferring B.V.
IPC分类号： C07K14/575 , C12P21/00
CPC分类号： C07K14/575 , A61K38/16 , C07K14/59 , C12P21/005
摘要： The present disclosure describes recombinant human chorionic gonadotropin (hCG) and methods for the production thereof. The recombinant hCG can include α2,3, α2,6, and, optionally, α2,8 sialylation. The recombinant hCG can be produced in a human cell line such as a PER.C6® cell line.
摘要翻译： 本公开描述了重组人绒毛膜促性腺激素（hCG）及其生产方法。 重组hCG可以包括α2,3，α2,6和任选的α2,8唾液酸化。 重组hCG可以在人细胞系如PER.C6细胞系中产生。
-
公开(公告)号：US20220275056A1
公开(公告)日：2022-09-01
申请号：US17690711
申请日：2022-03-09
申请人： Ferring B.V.
发明人： Ian Cottingham , Daniel Plaksin , Jérémy Duboeuf
摘要： A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
-
公开(公告)号：US20180282396A1
公开(公告)日：2018-10-04
申请号：US15532097
申请日：2015-12-01
申请人： Ferring B.V.
发明人： Ian Cottingham , Daniel Plaksin , Jérémy Duboeuf
IPC分类号： C07K14/715
摘要： A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
-
公开(公告)号：US11306136B2
公开(公告)日：2022-04-19
申请号：US16675621
申请日：2019-11-06
申请人： Ferring B.V.
发明人： Ian Cottingham , Daniel Plaksin , Jérémy Duboeuf
摘要： A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
-
公开(公告)号：US11292824B2
公开(公告)日：2022-04-05
申请号：US16709810
申请日：2019-12-10
申请人： Ferring B.V.
发明人： Ian Cottingham , Daniel Plaksin , Richard White
IPC分类号： C07K14/575 , C07K14/59 , C12P21/00 , A61K38/16
摘要： Described are pharmaceutical compositions comprising recombinant human chorionic gonadotropin (hCG) and follicle stimulating hormone (FSH), wherein the recombinant hCG in the composition comprises α2,3- and α2,6-sialylation and comprises mono-(1S), di-(2S), tri-(3S) and tetra-(4S) sialylated glycan structures. The recombinant hCG may be obtained by expression in a human cell line, such as the PER.C6 cell line, optionally wherein the cell line is modified using α2,3-sialyltransferase.
-
-
-
-
-
-
-
-
-
搜索结果
11 条记录 (耗时 0.014 秒)
